Patient charities ink deals to wrap up the Justice Department's co-pay kickback probe

Close-up of two people shaking hands with other people in the background
Two patient co-pay charities are settling with the feds to escape patient kickback allegations. (Pixabay)

An industrywide federal probe into drugmakers' use of charitable foundations to allegedly offer kickbacks for prescriptions of its drugs has netted some big fish in the last two years. Now, for the first time, two of the charities involved in the case have agreed to settle. 

Good Days and Patient Access Network Foundation will shell out a combined $6 million to close U.S. Department of Justice claims they operated as pharma front funds to effectively pay patients to take their drugs. 

Good Days President Clorinda Walley said in a statement the foundation would "continue to comply with all regulatory requirements surrounding charitable copay assistance programs and we welcome further clarity and (Office of the Inspector General) guidance to ensure we can continue to put patients in need first."

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

As part of the deal, Good Days agreed to pay $2 million while PAN Foundation will shell out $4 million. Neither foundation admitted wrongdoing. 

RELATED: Mallinckrodt hit with new kickback charges same day as $15.4M settlement with feds

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.